Sports Physical Therapy
Conditions
Keywords
Adapted Physical Activity program (APA), kinesiophobia, Fatigue, Quality of life
Brief summary
The objective of this study is to evaluate the effects of regular physical practice on fatigue, quality of life and kinesiophobia in patients treated at the ICO in Angers, regardless of the type of cancer and the type of treatment.
Detailed description
The objective of this study is to evaluate the effects of regular physical practice on fatigue, quality of life and kinesiophobia in patients treated at the ICO in Angers, regardless of the type of cancer and the type of treatment. A 12-week Adapted Physical Activity program (APA) is proposed to patients included in the study with an assessment of fatigue, quality of life, level of physical activity and kinesiophobia (fear of movement) at the beginning of the study. A second assessment of fatigue and quality of life will be done during the 6-week management. At the end of the program, a final evaluation of fatigue, quality of life and kinesiophobia will be done.
Interventions
Adults participating in the APA program at ICO during the first semester of 2020, regardless of cancer type and ongoing treatment (chemotherapy, radiotherapy, hormone therapy, immunotherapy). The APA program duration is : 12 weeks
Sponsors
Institut Cancerologie de l'Ouest
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Oncological care at the ICO 2. All types of cancer 3. Regardless of the type of treatment (chemotherapy, radiotherapy, hormone therapy, immunotherapy) 4. Age \> 18 years old 5. Follow the APA program at the ICO 6. Subject informed of the study
Exclusion criteria
1. Contraindication to the practice of sport 2. APA Program outside the ICO 3. Subject opposing the use of his data 4. Minor or adult patient under guardianship or curatorship 5. Pregnant woman 6. Altered general condition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life of Patients Participating in the 12-week Adapted Physical Activity Program. | 12 weeks | Describe the evolution of the quality of life of patients being treated for their cancer pathology at the ICO site in Angers, and participating in the 12-week adapted physical activity program at ICO. Quality of life is measured with the FACIT-F Fatigue and Quality of Life Questionnaire. The questionnaire is structured into five sections, each containing between 6 and 13 items. In total, it includes 40 items, each scored from 0 to 4: 0 - Not at all 1. \- A little 2. \- Moderately 3. \- Quite a bit 4. \- Very much By adding up the answers, the score range obtained is: 0 to 160. The higher the score, the less tired the patient is. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe Attendance at the APA Program. | 12 weeks | The number of sessions is planned by the APA coach at the beginning of the APA program. The number of performed sessions is measured. |
| Measure the Evolution of Kinesiophobia (Fear of Movement). | 12 weeks | Kinesiophobia is measured with the TAMPA Scale for Kinesiophobia (TSK-CF). This scale assesses the kinesiophobia index presented by the patient at the time of the assessment. The higher the score, the greater the level of kinesiophobia. Total score range: 17 to 68. Higher scores indicate greater fear of movement. A score ≥ 40 is considered significant kinesiophobia. |
| Measure Physical Activity at the Initiation of the APA Program. | Week 0 | The level of physical activity (PA) is assessed using the GPAQ questionnaire. The questionnaire consists of 16 items. Physical activity is expressed in MET-minutes per week (Metabolic Equivalent of Task), calculated from reported activity. Based on the score, three profiles are defined: High * ≥3 days vigorous activity (≥1500 MET-min/week) OR * ≥7 days walking/moderate/vigorous PA (≥3000 MET-min/week) Moderate * ≥20 min vigorous PA / day, ≥3 days/week OR * ≥30 min moderate PA/walking / day, ≥5 days/week OR * ≥5 days mixed activity (≥600 MET-min/week) Low * Does not meet above criteria |
Countries
France
Contacts
STUDY_CHAIRSophie ABADIE-LACOURTOISIE, MD
Institut de Cancérologie de l'Ouest
Participant flow
Recruitment details
Study start date first signed consent: 14 SEP 2020 Date of first patient inclusion: 14 SEP 2020 End of trial date (last visit of last patient): 14 MAR 2021
Pre-assignment details
All screened patients have been included
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 52.7 Years STANDARD_DEVIATION 11.5 |
| Region of Enrollment France | 37 Participants |
| Sex: Female, Male Female | 30 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
None listed